A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

Study Summary

The main aim of this study is to: * evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\] by investigator) of 2 dose levels of tarlatamab for Part 1 only * evaluate anti-tumor activity of tarlatamab as determined by objective response rate (ORR) per RECIST 1.1 by blinded independent central review (BICR) for Part 1 and 2 * evaluate safety of reduced mandatory monitoring period in Cycle 1 at selected dose of tarlatamab for Part 3

Conditions

Relapsed/Refractory Small Cell Lung Cancer

Interventions / Drugs

Tarlatamab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment222 participants

Primary Completion—

Lead SponsorAmgen

Data Retrieved2026-04-13 18:29:34.158005+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.